Phosphatidylinositol 3-kinase α (PI3Kα) inhibitors have been reported in a Synnovation Therapeutics Inc. patent as useful for the treatment of cancer, PIK3CA-related overgrowth spectrum, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities.
Nanjing Zenshine Pharmaceuticals Co. Ltd. has disclosed fused heterocyclic compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.
Researchers from Zhejiang University and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have reported the discovery of new phosphoinositide 3-kinase α (PI3Kα) inhibitors for the treatment of cancer.
Petra Pharma Corp. has patented phosphatidylinositol 3-kinase α (PI3Kα, PIK3CA) (H1047R mutant) allosteric inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA-related overgrowth spectrum.
Scorpion Therapeutics Inc. has disclosed urea derivatives acting as phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.
Researchers from Scorpion Therapeutics Inc. presented the discovery and preclinical evaluation of a novel mutant-selective, allosteric phosphoinositide 3-kinase α (PI3Kα) inhibitor, STX-478. In vitro, STX-478 showed mutant selectivity, as it selectively inhibited the viability of cell lines with mutations in the PIK3CA kinase domain and helical domain.
